Get the Stockscreener App
152.72
1.52%
-2.35
After Hours:
152.72
Glaukos Corp stock is traded at $152.72, with a volume of 672.33K.
It is down -1.52% in the last 24 hours and up +24.68% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$155.07
Open:
$154.05
24h Volume:
672.33K
Relative Volume:
0.69
Market Cap:
$8.97B
Revenue:
$551.35M
Net Income/Loss:
$-189.33M
P/E Ratio:
-46.40
EPS:
-3.2916
Net Cash Flow:
$-35.09M
1W Performance:
+2.95%
1M Performance:
+24.68%
6M Performance:
+35.25%
1Y Performance:
+43.33%
1-Day Range:
$143.11
$156.60
1-Week Range:
$143.11
$156.60
52-Week Range:
$73.16
$156.60
Glaukos Corp Stock (GKOS) Company Profile
Name
Glaukos Corp
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
152.72 | 9.11B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
93.93 | 164.43B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 125.40B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 105.46B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 52.59B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corp Stock (GKOS) Latest News
Price to sales forward of Glaukos Corp – XETR:6GJ - TradingView
Form 144 GLAUKOS Corp For: 9 July By Investing.com - Investing.com Australia
Form 144 GLAUKOS Corp For: 9 July - Investing.com UK
Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal
Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise - Stock Titan
Glaukos Corp CFO Alex Thurman sells $1.5m in shares - Investing.com
Form 4 Glaukos Corp For: 8 July By Investing.com - Investing.com Nigeria
Glaukos chief development officer Navratil sells $99,566 stock By Investing.com - Investing.com Nigeria
Glaukos (GKOS) CFO executes pre-planned share sale and option exercise - Stock Titan
Glaukos chief development officer Navratil sells $99,566 stock - Investing.com
Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan - Stock Titan
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
GKOS Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally? - Yahoo Finance
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 - Business Wire
Glaukos Corp stock and its role in eye disease treatment - ad-hoc-news.de
Form 144 GLAUKOS Corp For: 6 July By Investing.com - Investing.com Nigeria
Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares - Stock Titan
Glaukos stock rating reiterated at Outperform by William Blair - Investing.com
Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment - Quiver Quantitative
Glaukos stock hits 52-week high at 148.12 USD By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at 148.12 USD - Investing.com
Form 144 GLAUKOS Corp For: 1 July - Investing.com UK
Form 144 GLAUKOS Corp For: 1 July By Investing.com - Investing.com Canada
GKOS (GKOS) insider sells 3,630 shares total across April and June 2026 - Stock Titan
GKOS Reiterated by Piper Sandler -- Price Target Maintained at $165 - GuruFocus
Piper Sandler reiterates Glaukos stock rating on iDose headwinds By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Glaukos stock rating on iDose headwinds - Investing.com
Form 4 Glaukos Corp For: 29 June By Investing.com - Investing.com South Africa
Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding - Stock Titan
Form 4 Glaukos Corp For: 29 June - Investing.com UK
Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes - Stock Titan
Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares - Stock Titan
Enterprise value to EBIT forward of Glaukos Corp – XETR:6GJ - TradingView
Price to book forward of Glaukos Corp – XETR:6GJ - TradingView
Enterprise value to EBITDA forward of Glaukos Corp – XETR:6GJ - TradingView
Goldman Sachs Small Cap Equity Insights Fund's Glaukos Corp(GKOS) Holding History - GuruFocus
Glaukos Corp Actuals & Estimates (NYSE:GKOS) - TradingView
Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal
Glaukos completes enrollment in phase 2 blepharitis study - Investing.com
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis - BioSpace
Glaukos completes enrollment in phase 2 blepharitis study By Investing.com - Investing.com Australia
Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study - GuruFocus
Glaukos fills 275-patient trial of eyelid-disease drug candidate - Stock Titan
Glaukos Corp (GKOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Glaukos Corp For: 23 June By Investing.com - Investing.com Nigeria
Form 4 Glaukos Corp For: 23 June - Investing.com UK
Glaukos (NYSE: GKOS) director updates stock option grant to $106.52 strike - Stock Titan
Glaukos (NYSE: GKOS) director Leana Wen awarded 2,987 stock options at $106.52 - Stock Titan
GLAUKOS (GKOS) director Stapley gets 2,987 options at corrected $106.52 strike - Stock Titan
Glaukos Corp Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):